Metabolic syndrome (MetS) is a clustering of several cardiovascular risk factors that include: obesity, dyslipidemia, hypertension and high blood glucose, and often requires multidrug pharmacological interventions. The management of MetS therefore requires high healthcare cost, and can result in poor drug treatment compliance. Hence drug therapies that have pleiotropic beneficial effects may be...

(1) Background: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are a class of therapeutic agents that mimic the endogenous incretin hormone GLP-1. While this is not approved for Type Diabetes (T1DM) due to concern increased diabetic ketoacidosis (DKA) risk, long-acting GLP-1 medications being commonly prescribed off label T1DM in clinical practice. Several studies addressed efficacy and s...